CY71 Stock Overview
A clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Anixa Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.12 |
| 52 Week High | US$4.66 |
| 52 Week Low | US$2.02 |
| Beta | 0.85 |
| 11 Month Change | 4.70% |
| 3 Month Change | 6.85% |
| 1 Year Change | 4.00% |
| 33 Year Change | -0.64% |
| 5 Year Change | -7.69% |
| Change since IPO | -14.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| CY71 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.8% | 0.8% | 0.8% |
| 1Y | 4.0% | -18.3% | 8.6% |
Return vs Industry: CY71 exceeded the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: CY71 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| CY71 volatility | |
|---|---|
| CY71 Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CY71's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CY71's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 5 | Amit Kumar | www.anixa.com |
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer.
Anixa Biosciences, Inc. Fundamentals Summary
| CY71 fundamental statistics | |
|---|---|
| Market cap | €101.12m |
| Earnings (TTM) | -€11.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.6x
P/E RatioIs CY71 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CY71 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.36m |
| Earnings | -US$12.36m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CY71 perform over the long term?
See historical performance and comparison